{"status": "OK", "response": {"docs": [{"type_of_material": "Editorial", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "The news keeps getting worse about the value of hormone replacement therapies for postmenopausal women. Less than three months ago an international panel concluded that there was little evidence to support many of the presumed benefits of the treatments. Now federal health officials have halted a large study of hormone replacement therapy because the regimen used, a combination of estrogen and progestin, was doing more harm than good when taken for several years. The action has been met with shock and disbelief by many women and their doctors. The danger to any individual woman appears very slight. But this discouraging saga offers a sobering lesson in how aggressive marketing by the drug industry and a fervent desire for medical miracles on the part of patients and doctors can propel use of a drug far beyond that justified by scientific data.", "headline": {"main": "Hormone Therapy Woes"}, "abstract": "Editorial says decision by federal health officials to halt large study of hormone replacement therapy in postmenopausal women because of increase in breast cancer risk offers sobering lesson in how aggressive marketing by drug industry and fervent desire for medical miracles on part of patients and doctors can propel use of drugs far beyond that justified by scientific data (M)", "print_page": "22", "word_count": 674, "_id": "4fd21ac88eb7c8105d7999c9", "snippet": "The news keeps getting worse about the value of hormone replacement therapies for postmenopausal women. Less than three months ago an international panel concluded that there was little evidence to support many of the presumed benefits of the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2002/07/11/opinion/hormone-therapy-woes.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "ESTROGEN"}, {"name": "subject", "value": "HORMONES"}, {"name": "subject", "value": "MARKETING AND MERCHANDISING"}, {"name": "subject", "value": "BREAST"}, {"name": "subject", "value": "EDITORIALS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "WOMEN"}, {"name": "subject", "value": "PROGESTIN"}, {"name": "subject", "value": "MENOPAUSE"}], "byline": null, "document_type": "article", "pub_date": "2002-07-11T00:00:00Z", "section_name": "Health; Opinion"}], "meta": {"hits": 1, "offset": 0, "time": 35}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}